Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression…
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN…
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus…
DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated
Dubai, UAE , Oct. 18, 2025 (GLOBE NEWSWIRE) -- The DeFi market…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Jiuzi Holdings, Inc. (JZXN) Secures 100 Bitcoin via Private Placement, Signaling New Phase in Crypto Treasury Deployment
HANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN,…
Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the CMIC-III Less Invasive Study
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected…
Mobix Labs Moves Decisively with All-Cash $1.30 Per Share Offer for Peraso a 53% Premium That Signals New Phase of Growth
53% Premium All-Cash Offer Highlights Mobix Labs’ Momentum and Growth Vision October…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
